Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03878290 · ClinicalTrials.gov registry record · NA

RiSE to Prevent Cardiovascular Disease in African Americans

A NA study, sponsored by Loyola University.

Completed
Registry status
NA
Development phase
74
Enrollment target

NCT03878290 is a NA study that has completed, run by Loyola University. The registered enrollment target is 74 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03878290, a NA study, has completed, sponsored by Loyola University.

COMPLETED
Registry status
NA
Development phase
74 participants
Enrollment target

Study Summary

The purpose of this pilot study is to evaluate an innovative 8-wk stress reduction program called Resilience, Stress and Ethnicity (RiSE) program designed to reduce chronic stress associated with perceived discrimination among African Americans. African Americans residing in the Maywood community between the ages of 25 and 75 with at least one cardiovascular disease risk factor such as being overweight, having high blood pressure, or diabetes will be enrolled. The following specific aims will be addressed: Aim 1: Determine the feasibility and acceptability of the program as a strategy to reduce chronic stress in African Americans within the Maywood and surrounding community. Aim 2: Examine the extent to which training in RiSE (1) improves psychological well being, (2) decreases inflammatory burden, and (3) reduces cardiovascular risk in African Americans Participants will be randomized to either the RiSE program or the control (no intervention group). Participants will provide blood and saliva samples as well as complete written questionnaires asking them questions about their health, well-being, and early life at the start of the study, half way through the study (at 4 weeks), at the completion of the intervention (8 weeks) and 3 months after the completion of the intervention).

Interventions

  • BEHAVIORAL Resilience, Stress, and Ethnicity (RiSE)

Trial Details

FieldValue
Enrollment Target 74 participants
Start Date 2017-08-03
Est. Completion 2019-10-01
Phase NA

Sponsor

Loyola University

92 total trials

What the Registry Record Tells You About NCT03878290

The ClinicalTrials.gov registry entry for NCT03878290 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Loyola University, which has 92 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Resilience, Stress, and Ethnicity (RiSE) is the first listed.

NCT03878290 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03878290 about?

NCT03878290 is a clinical study titled "RiSE to Prevent Cardiovascular Disease in African Americans". The purpose of this pilot study is to evaluate an innovative 8-wk stress reduction program called Resilience, Stress and Ethnicity (RiSE) program designed to reduce chronic stress associated with perceived discrimination among African Americans. African Americans residing in the Maywood community be...

What is the current status of trial NCT03878290?

This trial is currently completed. It is a NA study. The enrollment target is 74 participants. The study started on 2017-08-03. Estimated completion is 2019-10-01.

What interventions are being tested in trial NCT03878290?

The interventions under investigation include: Resilience, Stress, and Ethnicity (RiSE) (BEHAVIORAL).

Who is sponsoring clinical trial NCT03878290?

This trial is sponsored by Loyola University, which has 92 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.